Kyverna Therapeutics is trading 7.2% up in pre-market at $8.19 amid September 9, 2026 disclosures at the Wells Fargo Healthcare Conference highlighting miv-cel’s progress toward a potential stiff-person-syndrome approval.
- Management reiterated plans to complete the rolling BLA in the fourth quarter.
- Updates described positive efficacy, safety, manufacturing, and reimbursement developments.
- Available coverage does not explicitly confirm the conference caused the gain; no September 10 company announcement was found.